Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection

Patients with chronic lymphocytic leukemia (CLL) show suboptimal responses to the vaccines against SARS-CoV-2; it has been shown though that a booster dose of the BNT162b2 vaccine may lead to a significant increase in the seroconversion rates of immunocompromised patients. We conducted a prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Diamantopoulos, Panagiotis T., Kontandreopoulou, Christina-Nefeli, Stafylidis, Christos, Vlachopoulou, Dimitra, Giannakopoulou, Nefeli, Vardaka, Maria, Mpouhla, Anthi, Variami, Eleni, Galanopoulos, Athanasios, Pappa, Vassiliki, Psichogiou, Mina, Hatzakis, Angelos, Viniou, Nora-Athina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589533/
https://www.ncbi.nlm.nih.gov/pubmed/36271935
http://dx.doi.org/10.1007/s00277-022-05003-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589533/
https://www.ncbi.nlm.nih.gov/pubmed/36271935
http://dx.doi.org/10.1007/s00277-022-05003-6

Ejemplares similares